CN Patent

CN115209884B — 含有格隆溴铵和盐酸奥达特罗的可吸入制剂

Assigned to Guangzhou Anovent Pharmaceutical Co Ltd · Expires 2024-05-28 · 2y expired

What this patent protects

本发明涉及液体药物制剂和通过在吸入器中雾化药物制剂来给药的方法。不含推进剂的药物制剂包括：(a)格隆溴铵或其盐(b)奥达特罗或其盐；(b)溶剂；(c)药理学上可接受的防腐剂，和(d)药理学上可接受的稳定剂，以及任选的其他药理学上可接受的添加剂。

USPTO Abstract

本发明涉及液体药物制剂和通过在吸入器中雾化药物制剂来给药的方法。不含推进剂的药物制剂包括：(a)格隆溴铵或其盐(b)奥达特罗或其盐；(b)溶剂；(c)药理学上可接受的防腐剂，和(d)药理学上可接受的稳定剂，以及任选的其他药理学上可接受的添加剂。

Drugs covered by this patent

Epipen (epinephrine) · Pfizer Inc.

Patent Metadata

Patent number: CN115209884B
Jurisdiction: CN
Classification: —
Expires: 2024-05-28
Drug substance claim: No
Drug product claim: No
Assignee: Guangzhou Anovent Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.